JP2015517565A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517565A5 JP2015517565A5 JP2015513277A JP2015513277A JP2015517565A5 JP 2015517565 A5 JP2015517565 A5 JP 2015517565A5 JP 2015513277 A JP2015513277 A JP 2015513277A JP 2015513277 A JP2015513277 A JP 2015513277A JP 2015517565 A5 JP2015517565 A5 JP 2015517565A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- diol
- alkyl
- independently
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002009 diols Chemical class 0.000 claims 16
- 239000003112 inhibitor Substances 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 208000002193 Pain Diseases 0.000 claims 12
- 229920000388 Polyphosphate Polymers 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 239000001205 polyphosphate Substances 0.000 claims 12
- 235000011176 polyphosphates Nutrition 0.000 claims 12
- 125000004103 aminoalkyl group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 102100040460 P2X purinoceptor 3 Human genes 0.000 claims 7
- 101710189970 P2X purinoceptor 3 Proteins 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 4
- 229930024421 Adenine Natural products 0.000 claims 4
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 229960000643 adenine Drugs 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 208000008035 Back Pain Diseases 0.000 claims 3
- 208000000094 Chronic Pain Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000000262 haloalkenyl group Chemical group 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 2
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims 2
- HPZMWTNATZPBIH-UHFFFAOYSA-N 1-methyladenine Chemical compound CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 claims 2
- CQOQCZLTCMUVMX-UHFFFAOYSA-N 2-[4-(2,3-dihydroxypropoxy)phenyl]acetamide Chemical compound NC(=O)CC1=CC=C(OCC(O)CO)C=C1 CQOQCZLTCMUVMX-UHFFFAOYSA-N 0.000 claims 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 claims 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 claims 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 2
- 208000006820 Arthralgia Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- HMFHBZSHGGEWLO-HWQSCIPKSA-N L-arabinofuranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@H]1O HMFHBZSHGGEWLO-HWQSCIPKSA-N 0.000 claims 2
- 102100040479 P2X purinoceptor 2 Human genes 0.000 claims 2
- 101710189968 P2X purinoceptor 2 Proteins 0.000 claims 2
- 102100037601 P2X purinoceptor 4 Human genes 0.000 claims 2
- 101710189967 P2X purinoceptor 4 Proteins 0.000 claims 2
- 102100037602 P2X purinoceptor 7 Human genes 0.000 claims 2
- 101710189965 P2X purinoceptor 7 Proteins 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 238000000586 desensitisation Methods 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000004031 partial agonist Substances 0.000 claims 2
- 230000002483 superagonistic effect Effects 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- 208000004371 toothache Diseases 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- SATCOUWSAZBIJO-UHFFFAOYSA-N 1-methyladenine Natural products N=C1N(C)C=NC2=C1NC=N2 SATCOUWSAZBIJO-UHFFFAOYSA-N 0.000 claims 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 claims 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims 1
- 206010029174 Nerve compression Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004452 carbocyclyl group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 239000002862 dinucleoside phosphate Substances 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 229940035893 uracil Drugs 0.000 claims 1
- 229940075420 xanthine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201209244A GB201209244D0 (en) | 2012-05-25 | 2012-05-25 | Compositions |
| GB1209244.1 | 2012-05-25 | ||
| PCT/GB2013/051377 WO2013175231A1 (en) | 2012-05-25 | 2013-05-24 | Dinuceloside polyphosphates for the treatment of pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015517565A JP2015517565A (ja) | 2015-06-22 |
| JP2015517565A5 true JP2015517565A5 (enExample) | 2016-07-14 |
Family
ID=46546668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513277A Pending JP2015517565A (ja) | 2012-05-25 | 2013-05-24 | 疼痛の治療のためのジヌクレオシドポリリン酸 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20150119352A1 (enExample) |
| EP (1) | EP2854821A1 (enExample) |
| JP (1) | JP2015517565A (enExample) |
| AU (1) | AU2013264966A1 (enExample) |
| CA (1) | CA2913313A1 (enExample) |
| GB (1) | GB201209244D0 (enExample) |
| HK (1) | HK1203054A1 (enExample) |
| WO (1) | WO2013175231A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| GB201320962D0 (en) * | 2013-11-27 | 2014-01-08 | Globalacorn Ltd | Compositions |
| WO2017209267A1 (ja) * | 2016-06-03 | 2017-12-07 | 塩野義製薬株式会社 | プリン誘導体 |
| CN112004551A (zh) | 2018-03-15 | 2020-11-27 | 丹米尔治疗有限责任公司 | 3”,5”-二烷氧基苯甲酰基-3’-氨基-3’-脱氧腺苷-5’-三磷酸及其药物用途 |
| US20230000063A1 (en) * | 2019-12-13 | 2023-01-05 | Chugai Seiyaku Kabushiki Kaisha | System for detecting extracellular purinergic receptor ligand, and non-human animal having the system introduced thereinto |
| US20230032473A1 (en) * | 2021-07-23 | 2023-02-02 | Wisconsin Alumni Research Foundation | Nad(h) nanoparticles and methods of use |
| CN114685588B (zh) * | 2022-05-05 | 2024-03-29 | 江苏申基生物科技有限公司 | 一种含开环核苷结构的起始加帽寡核苷酸引物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049550A (en) * | 1987-11-05 | 1991-09-17 | Worcester Foundation For Experimental Biology | Diadenosine 5', 5'"-p1, p4,-tetraphosphate analogs as antithrombotic agents |
| JP2783880B2 (ja) * | 1989-11-24 | 1998-08-06 | 富士レビオ株式会社 | 心臓病治療剤 |
| US5635160A (en) * | 1995-06-07 | 1997-06-03 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions |
| US5837861A (en) * | 1997-02-10 | 1998-11-17 | Inspire Pharmaceuticals, Inc. | Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency |
| US5681823A (en) * | 1996-05-02 | 1997-10-28 | Prp Inc. | P1, P4 -dithio-P2 -P3 -monochloromethylene 5', 5'"-diadenosine P1, P4 -tetraphosphate as antithrombotic agent |
| US6462028B2 (en) * | 1997-07-25 | 2002-10-08 | Inspire Pharmaceuticals, Inc. | Method of promoting cervical and vaginal secretions |
| GB2394419B (en) * | 2001-06-25 | 2005-09-07 | Inspire Pharmaceuticals Inc | Joint lubrication with p2y purinergic receptor agonists |
| CN1612739A (zh) * | 2001-11-06 | 2005-05-04 | 印斯拜尔药品股份有限公司 | 治疗或预防炎性疾病的方法 |
| EP1348466A3 (en) * | 2002-02-01 | 2003-10-29 | Inspire Pharmaceuticals, Inc. | Method for treating pain with adenosine-tetraphosphates |
| FR2842424A1 (fr) * | 2002-07-22 | 2004-01-23 | Univ Paris 7 Denis Diderot | Utilisation du nad ou de l'un de ses analogues, substrat des mono-adp-ribosyl tranferases, pour la preparation d'un medicament destine au traitement des pathologies liees aux recepteurs purinergiques |
| GB0502250D0 (en) * | 2005-02-03 | 2005-03-09 | Ic Vec Ltd | Use |
-
2012
- 2012-05-25 GB GB201209244A patent/GB201209244D0/en not_active Ceased
-
2013
- 2013-05-24 AU AU2013264966A patent/AU2013264966A1/en not_active Abandoned
- 2013-05-24 JP JP2015513277A patent/JP2015517565A/ja active Pending
- 2013-05-24 CA CA2913313A patent/CA2913313A1/en not_active Abandoned
- 2013-05-24 HK HK15103596.5A patent/HK1203054A1/xx unknown
- 2013-05-24 EP EP13725462.9A patent/EP2854821A1/en not_active Withdrawn
- 2013-05-24 WO PCT/GB2013/051377 patent/WO2013175231A1/en not_active Ceased
- 2013-05-24 US US14/403,560 patent/US20150119352A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517565A5 (enExample) | ||
| JP6671424B2 (ja) | リボシドの調製のための方法 | |
| CN109689672B (zh) | 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸 | |
| JP4265969B2 (ja) | ４′−置換ヌクレオシド | |
| ES2918585T3 (es) | Métodos para el tratamiento de infecciones por el virus Arenaviridae | |
| CN100387237C (zh) | 用于治疗乙型肝炎的β-L-2'-脱氧-核苷 | |
| JP6113185B2 (ja) | テロメラーゼ基質およびテロメア長作用因子としてのグアニンアナログ | |
| JP2010536787A5 (enExample) | ||
| JP2017526726A5 (enExample) | ||
| JP6538656B2 (ja) | ５’−ヌクレオチダーゼ阻害剤およびその治療的使用 | |
| JP2016531842A5 (enExample) | ||
| KR970701198A (ko) | 3'-치환 뉴클레오시드 유도체(3'-substituted nucleoside derivative) | |
| RU2017105743A (ru) | Модифицированные олигонуклеотиды, активирующие рнказу н | |
| JP2009541225A5 (enExample) | ||
| JP2003532640A5 (enExample) | ||
| JP6724909B2 (ja) | シリル化ピリミジンプロドラッグ及びその使用方法 | |
| JP2009530295A5 (enExample) | ||
| JP2015517565A (ja) | 疼痛の治療のためのジヌクレオシドポリリン酸 | |
| EP0998293A1 (en) | Cytokine related treatments of disease | |
| JP2013523717A5 (enExample) | ||
| CA2573977A1 (en) | Nicotinic receptor agonists for the treatment of inflammatory diseases | |
| CA2721586A1 (en) | Compositions containing antiviral compounds and methods of using the same | |
| JP2015533128A5 (enExample) | ||
| JP2008528665A5 (enExample) | ||
| CN1911237B (zh) | 用于治疗乙型肝炎的β-L-2＇-脱氧-核苷 |